Loading
PRAME is a cancer-testis antigen: a protein normally confined to the testis that about 90% of cutaneous melanomas and substantial fractions of ovarian, lung, endometrial and uveal cancers switch on. Because it sits inside the cell, drugs reach it only as peptide fragments displayed on HLA, through T-cell receptor bispecifics such as brenetafusp and TCR-T cells such as IMA203. This dossier gathers the 2 products (0 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Represses retinoic acid receptor signalling; drives proliferation and blocks differentiation; presented on HLA class I as peptides such as PRAME 425-433 on A*02:01.
| Modality | Phase 3 |
|---|---|
| Cell therapy 1 | |
| T-cell engager 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
PRISM-MEL-301 NCT06112314 | 3 | Recruiting | Untreated HLA-A*02:01-positive advanced cutaneous melanoma: brenetafusp + nivolumab vs nivolumab-based regimens | - | |
| 3 | Recruiting | A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301) | - | ||
| 1/2 | Recruiting | A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors | - | - | |
| 1/2 | Active | Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"PRAME" OR ABSTRACT:"PRAME") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRAME, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/prame.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/prame.json. Licence CC BY-NC 4.0.